Repay Prices Stonewall, Not Engagement

Summary: RPAY last closed at $3.47 on May 15, 2026 with a feed timestamp of 22:00:18 UTC on the Stooq end-of-day tape. That is 27.7% below Forager Capital's unsolicited $4.80 per share cash proposal from April 17, 2026. The market is acting as if the board's rejection settled the matter. The filings show a messier reality: a live rights plan, a second activist with an 8.6% stake pressing for board change, a pending KUBRA acquisition, and a company that just raised its 2026 adjusted EBITDA outlook. [1][2][3][4][5][6]

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Asymmetry	Main Reason to Reject
1	Repay prices stonewall, not engagement	U.S. / activist takeout / governance conflict / acquisition overhang	`RPAY` closed at $3.47 even after a public $4.80 cash proposal, a raised EBITDA guide, and activist pressure from two large holders.	Stooq close checked May 15, 2026; Forager proposal April 17, 2026; rights plan April 14, 2026; Veradace 13D/A April 28, 2026; board rejection and Q1 results May 4, 2026.	KUBRA expected to close in coming weeks; activist escalation can arrive on a short timeline.	Upside to the public bid is large; downside is real but visible.	Selected.
2	Prodways tender still prices a cheap stub	Europe / France small-cap industrial technology / asset sale / issuer tender	`ALPWG` closed at EUR0.794 while the proposed issuer tender sits at EUR1.10, and the post-tender stub still screens cheap on disclosed sale proceeds.	Stooq close checked May 15, 2026; official sale completion May 6, 2026; official OPRA project May 12, 2026.	End-May AMF process, then June 17, 2026 AGM.	Good long asymmetry on the math.	The desk already published this exact lane on May 14, 2026. It is not the best new article for this run.
3	Sunny Side Up tender spread is now too thin	Japan / tender offer / business integration	`2180.JP` closed at JPY 1,315 against Akatsuki's live JPY 1,320 tender.	Stooq close checked May 15, 2026; official tender launch and board support May 13, 2026.	Tender runs to June 30, 2026.	Legal path is visible.	The gross spread is too thin for a fresh desk note.
4	Wipro ADR screens cheap, but the wrapper is the whole problem	Broader Asia / India large-cap IT / tender buyback	`WIT` closed at $1.89 while Wipro approved a local-share buyback at INR 250, but ADS holders cannot tender ADSs directly.	Stooq close checked May 15, 2026; official buyback approval April 16, 2026; official ADS-holder notice April 22, 2026.	Shareholder approval, record-date mechanics, ADS cancellation, and proration.	The local premium is real on paper.	The U.S. wrapper is operationally inferior and weakens tradeability.

Selected opportunity: Repay Holdings Corporation (RPAY)

Why this one now: It is the freshest non-duplicate case where the market still treats a public bid and activist pressure as noise even after the company itself supplied better operating numbers.

What should surprise the reader: A stock can trade almost 28% below a public cash proposal and still not obviously be "cheap" if the board, the poison pill, and the pending acquisition are what the market thinks really matter.

Geographic Search Audit

U.S. candidate screened: Repay. Selected.
Japan candidate screened: SUNNY SIDE UP GROUP. Rejected because the spread to the live tender is too thin.
Broader Asia candidate screened: Wipro ADR. Rejected because ADS holders do not own the clean tender claim.
Europe / UK candidate screened: Prodways. Rejected because the desk already published the same stub-tender lane on May 14, 2026 after the required title scan.

Why This Is the Best Opportunity Right Now

The best opportunity is not the one with the neatest headline premium. It is the one where price, positioning, and catalyst are still visibly arguing with each other.

Repay fits that standard better than the other screened lanes. Prodways still works on the math, but the desk already shipped it. Sunny Side Up has a real cash offer, but the spread is too thin to deserve a fresh full note. Wipro's local buyback is real, yet the public U.S. wrapper is the wrong instrument. Repay is different. The quote still assumes the board's no is final, even though the bid is public, the activists are large, and the company's own operating release did not read like a distress file. [1][2][3][4][5][6]

What Should Surprise the Reader

The surprise is not that Repay drew a bid.

The surprise is that the stock still closed at $3.47 after a public $4.80 cash proposal, a raised EBITDA outlook, and evidence that activist pressure is not coming from one holder alone. [1][2][4][5][6] Between Forager's approximately 13% ownership and Veradace's filed 8.6% beneficial stake, more than a fifth of the Class A equity is already in openly dissatisfied hands, even though those holders have not filed as a group. [2][3]

That does not make a deal likely. It does make the market's indifference worth studying.

The Setup

Forager Capital went public on April 17, 2026 with an unsolicited, non-binding proposal to acquire Repay for $4.80 per share in cash. The letter said the proposal was not subject to a financing condition and that Forager had already reached out to management on April 13 for an exploratory discussion. [2]

Repay's board had already moved first. On April 13, 2026, the board adopted a stockholder rights plan and declared one preferred share purchase right for each outstanding Class A share, with the rights expiring on April 13, 2027 unless earlier redeemed. [5]

Then a second activist became louder. Veradace's April 28, 2026 Schedule 13D/A said the fund and related holders beneficially owned 8.6% of Repay's Class A shares and had delivered a notice nominating two directors for the 2026 annual meeting. [3]

On May 4, 2026, Repay's board formally rejected Forager's $4.80 proposal as significantly undervaluing the company. The same day, Repay also reported first-quarter results and raised its full-year adjusted EBITDA outlook to $141 million to $146 million, while saying the pending KUBRA acquisition was still expected to close in the coming weeks. [1][4][6]

That is the live setup: a public buyer, a rights plan, a second activist, a board rejection, and a pending acquisition that can either harden the board's stance or sharpen shareholder anger.

The Mispricing

Confirmed facts: the bid exists at $4.80 in cash; it is non-binding; the board rejected it; the rights plan exists; Veradace disclosed an 8.6% activist position and board nominations; Repay raised EBITDA guidance; and the stock last closed at $3.47. [1][2][3][4][5][6]

Inference: the market is assigning low odds to any engagement process that closes the gap between $3.47 and $4.80.

Reasonable but unverified speculation: either Forager, Veradace, or both can force more pressure than the current price implies, especially if shareholder dissatisfaction with KUBRA turns governance frustration into an active campaign.

The desk's variant view is narrower than a takeout call. Repay does not need a signed merger tomorrow for the stock to be misread. It only needs the market to stop treating the board's first rejection as economic finality.

Price

The latest checked market level is the May 15, 2026 Stooq close of $3.47 for RPAY, timestamped 22:00:18 UTC. [7]

That price matters because it sits far below the two clean public anchors:

Forager's public cash proposal at $4.80 per share. [2]
Forager's own stated unaffected reference, a 30-day VWAP of $2.75, which it used to frame the bid as a 75% premium. [2]

Against the current $3.47 quote, the public bid implies:

$1.33 per share upside, or 38.3%, to $4.80. [2][7]

Repay's own first-quarter filing complicates the price story in a useful way. Revenue was $80.8 million in Q1 2026 and adjusted EBITDA was $34.4 million. Full-year adjusted EBITDA guidance was raised to $141 million to $146 million. But cash and cash equivalents fell to $43.8 million from $115.7 million at year-end 2025, while long-term debt rose to $390.6 million from $280.1 million. [4][6]

So the market is not crazy to be skeptical. The stock is cheap to the bid because the process is messy, not because the company is obviously pristine.

Positioning

The positioning tension is unusually explicit.

Forager said it owns approximately 13% of the outstanding shares. [2] Veradace's filed stake is 8.6%, including common shares and options, and it disclosed director nominations tied to the 2026 annual meeting. [3]

That gives the tape a visible dissident base of roughly 21.6% of the Class A equity if you add the two figures arithmetically, though it is important not to overstate the point: they have not filed as a group, and aligned dissatisfaction is not the same thing as coordinated control. [2][3]

The rights plan also changes the positioning map. Repay's board adopted it immediately after the initial outreach, and the plan runs until April 13, 2027 unless earlier redeemed. [5] That means a bidder cannot simply keep buying stock and call that a process.

What I could not safely verify in this run: live borrow cost, short interest updates beyond older public filings, and listed-options liquidity. Those are material execution variables and remain explicitly uncertain here.

Catalyst

Repay's catalyst path is real but not single-date clean.

The pending KUBRA acquisition was still expected to close in the coming weeks as of the May 4 earnings release. [4][6]
Veradace has already escalated from criticism to director nominations. [3]
Forager can still seek engagement, sweeten, launch a different public pressure campaign, or let the board own the full consequences of refusing to engage. [2]
The rights plan can be redeemed by the board before the distribution date, which means it is a shield but not an irrevocable one. [5]

The market appears to be pricing only one branch of that tree: no deal, no process, and no forced rethink.

Payoff Map

The cleanest expression is long RPAY common stock.

This is not a clean merger-arb long and it is not a clean activist certainty trade. It is a governance-optional long where the public bid provides one anchor and the raised operating guide provides another.

The long thesis does not require a signed deal at $4.80 tomorrow. It only requires that the current quote be too dismissive about the chance of either engagement or a valuation reset once the market sees whether KUBRA closes cleanly and whether the board can contain two separate activist complaints at once.

I did not safely verify options chain liquidity or spreads in this run. Because of that, the desk does not default to options here.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	30%	$4.80	+38.3%	2 to 12 weeks	Forager pressure forces engagement, or the board opens a real review path instead of treating the April offer as closed history.	Medium
Base Case	40%	$4.00	+15.3%	2 to 16 weeks	The market rerates Repay on the combination of raised EBITDA guidance, ongoing activism, and the possibility that governance friction limits strategic drift even without a signed sale.	Medium-Low
Bottom Case	30%	$2.60	-25.1%	2 to 16 weeks	The board stonewalls successfully, KUBRA closes, takeover optionality fades, and the market prices leverage and governance risk more harshly.	Medium
Invalidation / Stop Condition	n/a	Below $2.80 after a clean KUBRA close and no active control process	Thesis broken	Immediate once visible	A durable tape below this zone would imply the market has stopped pricing even partial governance optionality.	Medium

Probability-weighted expected value: $3.82, or about +10.1% versus the latest checked close.

Current market price / level: RPAY $3.47

Timestamp: May 15, 2026, feed timestamp 22:00:18 UTC on the Stooq end-of-day tape

Primary instrument: RPAY common stock

Alternative expressions considered: Options rejected due insufficient live chain verification; short rejected because the quote already sits far below the public bid; pure merger-arb framing rejected because the proposal is still non-binding

Confidence: Medium-Low

What Would Prove This Wrong

The thesis fails if the market gets clear evidence that the optionality was illusory.

That can happen in three ways:

Forager backs away or goes silent without forcing any process. [2]
Veradace's campaign loses relevance, including through procedural defeat without any compensating shareholder response. [3]
KUBRA closes cleanly and investors decide the board's standalone path deserves more trust than the activists do. [1][4][5][6]

A falling stock price by itself is not enough. The failure condition is a falling stock price plus a fading process.

Risk Audit

Strongest counterargument: The board may simply be right. A non-binding $4.80 proposal can be financially real and still strategically insufficient. If KUBRA closes and management executes, the board may look stubborn now and correct later. [1][4][6]

Most fragile assumption: That activist pressure converts into action rather than endless grievance.

What the market may already know: The rights plan is live, the nomination path is procedurally messy, and the board may have more shareholder support than the public tone suggests. [3][5]

What could make the trade lose money even if the thesis is directionally right: Governance optionality can take longer than capital markets tolerate. A correct read on intrinsic value does not protect against a quarter or two of dead money.

Liquidity / execution risks: RPAY trades on Nasdaq and is more liquid than most desk micro-cap lanes, but event-driven longs can still gap hard on board or acquisition news. [7]

Leverage risks: The KUBRA transaction and higher debt burden are not cosmetic. They are part of why the market discounts the bid. [4][6]

Information reliability risks: Low on the bid, rights plan, and Q1 numbers because those are in official filings; higher on any inference about what unaffiliated shareholders will tolerate.

Invalidation trigger: A clean KUBRA close combined with no active control process and a sustained break below $2.80.

Publish / revise / reject recommendation: Publish.

Bottom Line

Repay is not trading like a company in a live process. It is trading like a company whose board already won.

That may turn out to be correct. But the public record is thinner than the tape implies. A $4.80 cash proposal exists. A rights plan exists because the board felt pressure quickly enough to adopt one. A second activist owns 8.6% and tried to nominate directors. Repay also just raised its EBITDA outlook while asking the market to trust a leveraged acquisition path. At $3.47, the stock prices rejection as if it settled the argument. The desk's variant view is that the argument is still live.

Research Quality Scorecard

The full scorecard is kept in the companion meta file.

Sources

Best Trade Strategy

Best trade: Long RPAY common stock. Options were not safely verified in this run.